Hyperpigmentation following Treatment of Frontal Fibrosing Alopecia

Introduction: Frontal fibrosing alopecia (FFA) is a scarring alopecia characterized by progressive recession of the frontotemporal hairline. Current treatment is aimed at stopping progression, and the combination of dutasteride and pimecrolimus is the most effective therapy. Side effects associated...

Full description

Bibliographic Details
Main Authors: Pérez Rodríguez, Irma Margarita, García Melendez, Martha Elena, Eichelmann, Kristian, Vázquez Martínez, Osvaldo Tomás, Ocampo Candiani, Jorge
Format: Article
Language:English
Published: 2013
Online Access:http://eprints.uanl.mx/14668/1/401.pdf
_version_ 1824414107379433472
author Pérez Rodríguez, Irma Margarita
García Melendez, Martha Elena
Eichelmann, Kristian
Vázquez Martínez, Osvaldo Tomás
Ocampo Candiani, Jorge
author_facet Pérez Rodríguez, Irma Margarita
García Melendez, Martha Elena
Eichelmann, Kristian
Vázquez Martínez, Osvaldo Tomás
Ocampo Candiani, Jorge
author_sort Pérez Rodríguez, Irma Margarita
collection Repositorio Institucional
description Introduction: Frontal fibrosing alopecia (FFA) is a scarring alopecia characterized by progressive recession of the frontotemporal hairline. Current treatment is aimed at stopping progression, and the combination of dutasteride and pimecrolimus is the most effective therapy. Side effects associated with dutasteride are erectile dysfunction as well as breast tenderness and enlargement, while pimecrolimus produces a burning sensation. Case Report: We present a 57-year-old postmenopausal female with a 3-year history of a scarring alopecic plaque in her frontotemporal region. Biopsy confirmed the diagnosis of FFA, and she was started on dutasteride 0.5 mg p.o. q.d., and later, topical pimecrolimus 1% b.i.d. was added. Eight months after initiating treatment, she showed hyperpigmentation on her metacarpophalangeal and interphalangeal joints, as well as on the cheeks and on the chin; dutasteride and pimecrolimus were discontinued. After 5 months of follow-up, her hyperpigmentation improved by 80% only by using photoprotection. Conclusion: Because of the variable clinical course of FFA, treatment is focused on halting its progression. Several therapeutic agents have been evaluated and the combination of dutasteride and pimecrolimus has shown a high response rate. There is no reported evidence of hyperpigmentation associated with this combination.
format Article
id eprints-14668
institution UANL
language English
publishDate 2013
record_format eprints
spelling eprints-146682022-04-07T21:59:34Z http://eprints.uanl.mx/14668/ Hyperpigmentation following Treatment of Frontal Fibrosing Alopecia Pérez Rodríguez, Irma Margarita García Melendez, Martha Elena Eichelmann, Kristian Vázquez Martínez, Osvaldo Tomás Ocampo Candiani, Jorge Introduction: Frontal fibrosing alopecia (FFA) is a scarring alopecia characterized by progressive recession of the frontotemporal hairline. Current treatment is aimed at stopping progression, and the combination of dutasteride and pimecrolimus is the most effective therapy. Side effects associated with dutasteride are erectile dysfunction as well as breast tenderness and enlargement, while pimecrolimus produces a burning sensation. Case Report: We present a 57-year-old postmenopausal female with a 3-year history of a scarring alopecic plaque in her frontotemporal region. Biopsy confirmed the diagnosis of FFA, and she was started on dutasteride 0.5 mg p.o. q.d., and later, topical pimecrolimus 1% b.i.d. was added. Eight months after initiating treatment, she showed hyperpigmentation on her metacarpophalangeal and interphalangeal joints, as well as on the cheeks and on the chin; dutasteride and pimecrolimus were discontinued. After 5 months of follow-up, her hyperpigmentation improved by 80% only by using photoprotection. Conclusion: Because of the variable clinical course of FFA, treatment is focused on halting its progression. Several therapeutic agents have been evaluated and the combination of dutasteride and pimecrolimus has shown a high response rate. There is no reported evidence of hyperpigmentation associated with this combination. 2013 Article PeerReviewed text en cc_by_nc_nd http://eprints.uanl.mx/14668/1/401.pdf http://eprints.uanl.mx/14668/1.haspreviewThumbnailVersion/401.pdf Pérez Rodríguez, Irma Margarita y García Melendez, Martha Elena y Eichelmann, Kristian y Vázquez Martínez, Osvaldo Tomás y Ocampo Candiani, Jorge (2013) Hyperpigmentation following Treatment of Frontal Fibrosing Alopecia. Case reports in dermatology, 5 (3). pp. 357-362. ISSN 1662-6567 http://doi.org/10.1159/000357022 doi:10.1159/000357022
spellingShingle Pérez Rodríguez, Irma Margarita
García Melendez, Martha Elena
Eichelmann, Kristian
Vázquez Martínez, Osvaldo Tomás
Ocampo Candiani, Jorge
Hyperpigmentation following Treatment of Frontal Fibrosing Alopecia
thumbnail https://rediab.uanl.mx/themes/sandal5/images/online.png
title Hyperpigmentation following Treatment of Frontal Fibrosing Alopecia
title_full Hyperpigmentation following Treatment of Frontal Fibrosing Alopecia
title_fullStr Hyperpigmentation following Treatment of Frontal Fibrosing Alopecia
title_full_unstemmed Hyperpigmentation following Treatment of Frontal Fibrosing Alopecia
title_short Hyperpigmentation following Treatment of Frontal Fibrosing Alopecia
title_sort hyperpigmentation following treatment of frontal fibrosing alopecia
url http://eprints.uanl.mx/14668/1/401.pdf
work_keys_str_mv AT perezrodriguezirmamargarita hyperpigmentationfollowingtreatmentoffrontalfibrosingalopecia
AT garciamelendezmarthaelena hyperpigmentationfollowingtreatmentoffrontalfibrosingalopecia
AT eichelmannkristian hyperpigmentationfollowingtreatmentoffrontalfibrosingalopecia
AT vazquezmartinezosvaldotomas hyperpigmentationfollowingtreatmentoffrontalfibrosingalopecia
AT ocampocandianijorge hyperpigmentationfollowingtreatmentoffrontalfibrosingalopecia